EU/3/17/1872

About

On 22 May 2017, orphan designation (EU/3/17/1872) was granted by the European Commission to Miragen Therapeutics Europe Ltd, United Kingdom, for chimeric locked nucleic acid deoxynucleoside phosphorothioate-linked oligonucleotide inhibitor directed against microRNA-155-5p (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma.

The sponsorship was transferred to miRagen Therapeutics S.à r.l., Luxemburg in May 2019.

Key facts

Active substance
Chimeric locked nucleic acid deoxynucleoside phosphorothioate-linked oligonucleotide inhibitor directed against microRNA-155-5p
Disease / condition
Treatment of cutaneous T-cell lymphoma
Date of first decision
22/05/2017
Outcome
Positive
EU designation number
EU/3/17/1872

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

miRagen Therapeutics S.à r.l.
14 Rue Edward Steichen
2540 Luxemburg
Luxembourg
E-mail: info@miragenrx.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating